Results 31 to 40 of about 28,958 (244)
Archives of Pharmacy Practice, 2016 Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin.
Amal K Sulieman
doaj +1 more source
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj +1 more source
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +3 more sources
PLoS ONE, 2019 BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke +7 more
doaj +1 more source
Determination of Dabigatran Concentration in Human Plasma and Breast Milk
International Journal of Analytical Chemistry, 2021 Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, 2020 Our study aimed to determine the impact of genetic polymorphisms of ABCB1 and CES1 on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran in patients with nonvalvular atrial fibrillation (NVAF).
Qiuyi Ji +5 more
semanticscholar +1 more source
Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke
Stroke, 2020 Supplemental Digital Content is available in the text. Background and Purpose— Patients with transient ischemic attack (TIA) and minor ischemic stroke are at risk for early recurrent cerebral ischemia.
K. Butcher +14 more
semanticscholar +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2020 The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD +5 more
doaj +1 more source
Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC
Angewandte Chemie International Edition, EarlyView.An ultrapotent yet fully reversible trivalent thrombin inhibitor discovered through screening a large dynamic combinatorial library (DCL) of 125 000 members of self‐assembled fragments. The innovative approach leverages size‐exclusion‐based affinity selection, coupled with MALDI‐TOF mass spectrometry readout, enabling the full workflow to be completed ...
Millicent Dockerill +2 more
wiley +1 more source
Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
Clinical and Applied Thrombosis/Hemostasis, 2019 To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj +1 more source